Guyana vs Middle East, North Africa, Afghanistan & Pakistan: Immunization, Hib3
Immunization, Hib3 over time
- Guyana
- Middle East, North Africa, Afghanistan & Pakistan
How they compare
Guyana currently reports 98.0% against 84.5% in Middle East, North Africa, Afghanistan & Pakistan, a difference of 13.5%.
That makes Guyana's figure about 1.2 times Middle East, North Africa, Afghanistan & Pakistan's.
Across all 24 years both countries report, Guyana has been ahead every year.
Guyana ranks 20th and Middle East, North Africa, Afghanistan & Pakistan ranks 19th of 191 countries.
Guyana has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Guyana | Middle East, North Africa, Afghanistan & Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 92.0% | 17.3% | 74.7% | Guyana |
| 2010s | 96.4% | 69.8% | 26.6% | Guyana |
| 2020s | 98.2% | 83.4% | 14.8% | Guyana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Guyana or Middle East, North Africa, Afghanistan & Pakistan?
- Guyana, at 98.0% against 84.5% in Middle East, North Africa, Afghanistan & Pakistan as of 2024.
- What is the difference in immunization, hib3 between Guyana and Middle East, North Africa, Afghanistan & Pakistan?
- 13.5%, with Guyana ahead.
- How many years of comparable data are there for Guyana and Middle East, North Africa, Afghanistan & Pakistan?
- 24 years are reported by both, from 2001 to 2024.
- How do Guyana and Middle East, North Africa, Afghanistan & Pakistan rank globally for immunization, hib3?
- Guyana ranks 20th and Middle East, North Africa, Afghanistan & Pakistan ranks 19th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.